Mission Statement, Vision, & Core Values of Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc.'s strategic foundation-its Mission, Vision, and Core Values-is not just corporate language; it's the engine driving the company's recent financial pivot, which saw third quarter 2025 revenue jump by an impressive 78% sequentially. You're looking at a company shifting its entire distribution model to more directly address the estimated 1 billion people worldwide who suffer from Obstructive Sleep Apnea (OSA), a condition that remains 90% undiagnosed. How does a medical technology firm, which posted a net loss of $14.3 million for the first nine months of 2025, rationalize a strategic pivot that includes a major acquisition like The Sleep Center of Nevada? This core belief system is what translates their proprietary, non-surgical treatment into a path for maximizing both patient health and shareholder value-but are the stated values truly aligned with the aggressive new direct-to-patient strategy?

Vivos Therapeutics, Inc. (VVOS) Overview

You need a clear picture of Vivos Therapeutics, Inc.'s trajectory, and the recent financial reports show a company in the middle of a major, high-growth strategic shift. The direct takeaway is this: Vivos is successfully pivoting its business model, and that move is driving record revenue growth, with Q3 2025 revenue hitting $6.8 million, a 76% year-over-year jump.

Vivos Therapeutics, Inc. was founded in 2016 and is headquartered in Littleton, Colorado, with a core mission to tackle the massive public health issue of sleep-disordered breathing (SDB), particularly obstructive sleep apnea (OSA). Their flagship product is The Vivos Method, a non-surgical, non-invasive, and non-pharmaceutical treatment. It uses the proprietary Vivos System-custom-designed oral appliances, a digital workflow, and a structured treatment protocol-to address the underlying craniofacial anatomy causing airway issues.

The company's current sales reflect a deliberate pivot away from a reliance on a legacy dental industry distribution channel. For the nine months ended September 30, 2025, total revenue reached $13.6 million. This shift is all about moving toward direct affiliation with, or acquisition of, medical sleep practices, like the June 2025 acquisition of The Sleep Center of Nevada (SCN). This new model allows Vivos to capture both diagnostic and treatment revenue streams more directly from patients who need their solutions.

If you want to dig deeper into the investors who are backing this new direction, you can check out Exploring Vivos Therapeutics, Inc. (VVOS) Investor Profile: Who's Buying and Why?

Q3 2025 Financial Performance and Strategic Pivot

Honestly, the third quarter of 2025 was a game-changer for Vivos Therapeutics. Total revenue for the quarter was $6.8 million, representing a 76% increase compared to the same period in 2024. That's a huge sequential jump, too, up 78% over Q2 2025, which really validates the strategic pivot. The quick math here is that the Sleep Center of Nevada (SCN) acquisition is already paying off, showcasing the benefits of a full quarter of operations under the new model.

The revenue growth is a mix of product and service sales, but the service side is where the new model shines. The increase in revenue included an additional $2.7 million in service revenue. This was largely driven by:

• $2.2 million from OSA sleep testing services, primarily generated by SCN.
• $1.3 million from new treatment centers launched at SCN locations in Las Vegas.

Product sales are also strong, with the company reporting that in Q1 2025 alone, they shipped a record 3,736 oral appliance arches, an 87% increase year-over-year. What this estimate hides, still, is the high operating cost of integrating a new acquisition; the operating loss for Q3 2025 increased to $4.7 million, reflecting key investments in people and infrastructure to get SCN to full capacity. But, the gross profit for the quarter was still a healthy $3.9 million.

A Leader in Non-Invasive Sleep Apnea Treatment

Vivos Therapeutics, Inc. is defintely positioning itself as a leader in the medical device and healthcare services sector focused on sleep-related breathing disorders. You have to remember the context: Obstructive Sleep Apnea (OSA) affects over 1 billion people worldwide, and a staggering 90% remain undiagnosed. Vivos offers a non-CPAP (Continuous Positive Airway Pressure) solution, which is a huge market opportunity given the high non-compliance rates with traditional machines.

Their proprietary Complete Airway Repositioning and Expansion (CARE) devices are a key differentiator. They are the only U.S. Food and Drug Administration (FDA) 510(k) cleared technology for treating severe OSA in adults, and they were the first to receive clearance for treating moderate-to-severe OSA in children aged 6 to 17. That's a major regulatory and clinical advantage. Plus, the patient preference is clear: nearly two-thirds of patients at their new centers are choosing the Vivos oral appliances over CPAP, with the average case value exceeding $5,000. This is why Vivos is a company you need to watch closely as they scale their new model.

Vivos Therapeutics, Inc. (VVOS) Mission Statement

You're looking for the core purpose that drives Vivos Therapeutics, Inc.'s strategy, especially with their big pivot in 2025. The company's mission is direct and powerful: to rid the world of obstructive sleep apnea (OSA). This isn't just a corporate slogan; it's the definitive guide for their operational shift and product development, mapping a clear path to address a massive, underserved global health problem.

A mission statement's significance is in its ability to focus capital and human effort. For Vivos Therapeutics, this mission dictates the move away from their legacy dentist-focused model toward a more direct, patient-centric sleep center strategy, highlighted by the June 2025 acquisition of The Sleep Center of Nevada (SCN). [cite: 9 from previous step] That acquisition alone is a concrete step toward their vision, which is to provide medical and dental professionals with access to OSA screening and treatment protocols for their patients.

Here's the quick math: with over 1 billion people worldwide affected by OSA, and 90% of them remaining undiagnosed, the market opportunity is vast, and the humanitarian need is even greater. [cite: 7 from previous step] This mission grounds the company's aggressive growth strategy in a compelling, empathetic purpose.

Core Component 1: Global Patient Impact and Health Focus

The first core component of the mission is a relentless focus on global patient impact, aiming to provide hope and allow patients to 'Breathe New Life.' [cite: 13 from previous step] The company isn't just treating a symptom; it's addressing a chronic disorder closely linked to many serious health conditions. [cite: 7 from previous step]

This commitment is evident in their shift to capture both diagnostic and treatment revenue, accelerating patient access. The acquisition of The Sleep Center of Nevada (SCN) in June 2025 immediately contributed to this goal, adding $2.2 million in diagnostic sleep testing revenue and $1.3 million in new treatment center revenue in the third quarter of 2025 alone. [cite: 2 from previous step] That's a strong, measurable step toward their goal. To be fair, this strategic pivot initially caused a widening of the operating loss to $4.9 million in the second quarter of 2025 as they invested in scaling the new model, but it's a necessary cost to achieve the mission's scale. [cite: 9 from previous step]

• Address the 90% undiagnosed OSA population. [cite: 7 from previous step]
• Provide a non-surgical, non-pharmaceutical solution. [cite: 13 from previous step]
• Prioritize patient access over simple financial returns.

Core Component 2: Proprietary, Clinically-Effective Innovation

The second pillar is the commitment to groundbreaking technology and clinical effectiveness, embodied by The Vivos Method. This proprietary, multidisciplinary treatment protocol is a clinical breakthrough for OSA often caused by craniofacial anatomy development.

The company's Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children ages 6 to 17. [cite: 7 from previous step, 8 from previous step] This regulatory validation is a critical moat. In the first quarter of 2025, Vivos Therapeutics sold 3,736 oral appliance arches, generating approximately $1.8 million in product revenue, an 8% increase year over year, which shows the growing market acceptance of their core innovative product. [cite: 1 from previous step] This focus on innovation is defintely what separates them from simple mandibular advancement devices.

Core Component 3: Provider Empowerment and Scalable Distribution

The final core component is the strategic focus on empowering healthcare providers to deliver The Vivos Method efficiently. The company's vision explicitly states they provide medical and dental professionals with access to the protocols. This is an acknowledgment that to 'rid the world of OSA,' they must scale beyond their direct reach.

The 2025 strategic pivot is the clearest evidence of this component in action. By the end of the third quarter of 2025, Vivos Therapeutics' total revenue reached $13.6 million for the nine months, a result of the shift toward sleep center provider-based alliances and acquisitions. [cite: 2 from previous step] Management is aiming to reach cash flow breakeven in the fourth quarter of 2025, driven by the deployment of additional Sleep Optimization (SO) teams and expanded facility capacity in the new model. [cite: 9 from previous step] The ultimate goal is to establish The Vivos Method as a primary treatment option and standard of care globally. You can find more details on their business model and strategic evolution here: Vivos Therapeutics, Inc. (VVOS): History, Ownership, Mission, How It Works & Makes Money.

Vivos Therapeutics, Inc. (VVOS) Vision Statement

You're looking at Vivos Therapeutics, Inc. (VVOS) right now because their business model is in a critical pivot, and the vision is the map for that change. The core takeaway is simple: Vivos is shifting its focus from a dental-centric distribution channel to becoming a full-spectrum medical device and healthcare services company, aiming to be the leader in non-invasive obstructive sleep apnea (OSA) treatment. This vision is directly tied to the 78% sequential revenue growth they saw in the third quarter of 2025, which proves the new model is taking hold.

The company's vision is to lead the medical device and healthcare services industry in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep-related breathing disorders, ultimately providing hope to allow patients to Breathe New Life. This isn't just marketing fluff; it's a tangible shift from a product company to a service-and-product company, which is a much more defensible position. Honestly, the market is huge-millions of Americans suffer from OSA-so the vision is appropriately ambitious.

The Vision: Leading the Shift to Non-Invasive Sleep Treatment

The Vivos vision is about market leadership, specifically by championing a non-surgical, non-pharmaceutical solution-The Vivos Method-for a chronic disease. To be fair, this is a high-risk, high-reward strategy. It requires them to fundamentally change how Obstructive Sleep Apnea (OSA) is treated in the US, moving it beyond the traditional Continuous Positive Airway Pressure (CPAP) machine. Their acquisition of The Sleep Center of Nevada (SCN) in June 2025 is a concrete step in this direction, giving them direct patient access and immediate service revenue.

Here's the quick math on the pivot's impact: Total revenue for the third quarter of 2025 was $6.8 million, a 76% increase year-over-year, largely driven by the new service model. What this estimate hides, still, is the cost of that pivot; the net loss for the first nine months of 2025 climbed to $14.3 million, reflecting the increased operating expenses for the acquisition and integration. That's the cost of executing a bold vision.

• Focus: Non-surgical, non-pharmaceutical OSA treatment.
• Action: Acquire sleep-focused medical practices.
• Result: 78% sequential revenue growth in Q3 2025.

The Mission: Delivering The Vivos Method Through Direct Patient Access

The mission is the tactical plan for the vision: to develop and commercialize innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues, particularly through a new marketing and distribution model. This means moving away from the legacy Vivos Integrated Provider (VIP) fee revenue model, which relied on dentists, and towards provider-based acquisitions and alliances.

The core product is The Vivos Method, a proprietary, clinically effective solution for all severities of OSA in adults and moderate-to-severe OSA in children. The mission is to get this FDA-cleared technology in front of far more patients by controlling the diagnostic and treatment delivery process. For example, the SCN acquisition allows Vivos to capture both OSA diagnostic and treatment revenue, which diversifies the income stream. This is defintely a smarter, more integrated approach than relying solely on third-party provider enrollment.

Core Values: Innovation, Clinical Efficacy, and Patient-Centricity

As a seasoned analyst, I see the core values of Vivos Therapeutics, Inc. expressed not just in words, but in their product and strategy. They value Innovation, evidenced by their patented technology and their willingness to pioneer a new distribution model. They value Clinical Efficacy, which is non-negotiable for a medical device company-their devices are FDA-cleared for all severity levels of adult OSA.

Plus, they show a clear commitment to Patient-Centricity. The Vivos Method is non-invasive and non-surgical, offering a gentler alternative to traditional treatments. The entire pivot to direct patient access is a move to shorten the path between a patient in need and the proprietary treatment. This focus is crucial for long-term brand equity and adoption. If you want to dive deeper into the financial implications of this strategic shift, you should read Breaking Down Vivos Therapeutics, Inc. (VVOS) Financial Health: Key Insights for Investors. It's all about mapping these strategic pillars to the balance sheet.

Vivos Therapeutics, Inc. (VVOS) Core Values

You're looking for the bedrock principles that guide Vivos Therapeutics, Inc.'s strategic shift, and it's a smart move. When a company pivots its business model, its core values are what keep the ship pointed in the right direction. For Vivos, the values are less about corporate platitudes and more about the tangible actions they took in the 2025 fiscal year, particularly the move from a pure dental-focused model to a medical-sleep-center-based approach. The direct takeaway is that their values are now fundamentally tied to patient-centric access and strategic growth through medical integration.

Here's the quick math on why this matters: their strategic pivot to focus on provider-based alliances and acquisitions, like The Sleep Center of Nevada (SCN), is driving their 2025 results. This shift is a direct reflection of their priorities, and you can see it in their Q3 2025 revenue of $6.8 million, which was up 76% year-over-year.

Patient Access & Clinical Efficacy

This value is about getting The Vivos Method-a non-surgical, non-invasive, and non-pharmaceutical solution for obstructive sleep apnea (OSA)-to the millions of people who need it. OSA affects over 1 billion people worldwide, and Vivos recognizes that 90% remain undiagnosed. The company's commitment here is defintely not just talk; it's a matter of life-changing treatment.

The core of this value is the clinical proof and reach of their technology. Their Complete Airway Repositioning and Expansion (CARE) devices are the only U.S. Food and Drug Administration (FDA) 510(k) cleared technology for treating all severity levels of OSA in adults, and for moderate-to-severe OSA in children aged 6 to 17. This clearance is a huge differentiator. The company's commitment to efficacy was further demonstrated in September 2025 with the announcement of first-time, peer-reviewed published data confirming their Vivos DNA appliance is both safe and efficacious in treating pediatric OSA.

• FDA Clearance: The only device cleared for all adult OSA severities.
• Pediatric Data: Published clinical data in September 2025 confirmed the appliance's safety and efficacy in children.
• Patient Reach: As of the end of 2024, approximately 58,000 patients worldwide had been treated with Vivos' patented oral appliances.

Strategic Innovation & Technology

Vivos Therapeutics doesn't just sell a product; they commercialize an innovative diagnostic and treatment method. This value is their engine for growth, focusing on proprietary, clinically effective solutions. The innovation isn't just in the appliance itself, but in the entire delivery system, which they call The Vivos Method.

The biggest strategic innovation in 2025 was the pivot to a direct medical affiliation model. This is where the rubber meets the road. The June 2025 acquisition of The Sleep Center of Nevada (SCN) was a key move, allowing Vivos to capture both OSA diagnostic and treatment revenue. Within just twenty days post-acquisition in Q2 2025, SCN generated approximately $500,000 in diagnostic sleep testing services revenue, proving the model works immediately. This move is designed to put their highly effective OSA diagnostic tools and therapies in front of far more patients, creating powerful new revenue streams.

You can see the impact of this new model in the Q3 2025 results, where SCN added $2.2 million in diagnostic sleep testing revenue and $1.3 million in a new 'treatment center' revenue stream. That's a clear return on an innovation in their business strategy.

Provider Partnership & Empowerment

The company's shift is fundamentally about empowering a broader range of healthcare providers. They are moving away from a model reliant on Vivos Integrated Practice (VIP) service revenue to one focused on provider-based acquisitions or alliances. This isn't just a sales tactic; it's a recognition that solving the OSA crisis requires a multidisciplinary approach, bridging the gap between dental and medical sleep practices.

Their actions in 2025 show this commitment. Beyond the SCN acquisition, they developed an updated sleep practice management model for practices not interested in being purchased. For example, in July 2025, Vivos entered into its first such management agreement with MISleep Solutions LLC in Michigan, where Vivos owns a supermajority equity stake in the management services company, with the sleep doctors retaining a minority interest. This structure ensures alignment and allows the sleep doctors to offer the full Vivos suite of treatments. This is a smart, flexible way to scale the model, and Vivos is actively looking to replicate this in other states. This is how you build a scalable healthcare network.

The financial impact of this pivot is also visible in their cost structure. Operating expenses for Q1 2025 were $5.4 million, a decrease of 5% compared to the same period in 2024, reflecting continued cost-cutting in sales and marketing as they transition to this new, more efficient distribution model. If you want to dive deeper into the financial mechanics of this strategic shift, you should read Exploring Vivos Therapeutics, Inc. (VVOS) Investor Profile: Who's Buying and Why?

Actionable Insight: Look for Vivos to announce similar management agreements or acquisitions in Q4 2025 and Q1 2026. This expansion of the Provider Partnership model is the key driver for their anticipated long-term revenue growth.